Literature DB >> 24172153

Hepatitis C virus late relapse after sustained virologic response from interferon and ribavirin treatment as confirmed by RNA sequencing.

Yidan Lu1, Anton Andonov, David K H Wong.   

Abstract

Hepatitis C virus (HCV) viremia is unusual (<5%) after successful treatment, defined as sustained virologic response (SVR) or undetectable HCV PCR 12 to 24 weeks after therapy. We present a case of late virologic relapse (de novo infection was excluded by RNA sequencing) after SVR followed by spontaneous viral clearance.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24172153      PMCID： PMC3911426          DOI： 10.1128/JCM.01367-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  14 in total

1.  Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting.

Authors:  C P Desmond; S K Roberts; F Dudley; J Mitchell; C Day; S Nguyen; S Pianko
Journal:  J Viral Hepat       Date:  2006-05       Impact factor: 3.728

Review 2.  Occult hepatitis C: how convincing are the current data?

Authors:  Martin-Walter Welker; Stefan Zeuzem
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

3.  Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses.

Authors:  Naga Suresh Veerapu; Sukanya Raghuraman; T Jake Liang; Theo Heller; Barbara Rehermann
Journal:  Gastroenterology       Date:  2010-10-30       Impact factor: 22.682

4.  Relapse of hepatitis C in a pegylated-interferon-alpha-2b plus ribavirin-treated sustained virological responder.

Authors:  Hideki Fujii; Yoshito Itoh; Naoki Ohnishi; Masafumi Sakamoto; Tohru Ohkawara; Yoshihiko Sawa; Koichi Nishida; Takeshi Nishimura; Kanji Yamaguchi; Kohichiroh Yasui; Masahito Minami; Takeshi Okanoue; Yasuo Ohkawara; Toshikazu Yoshikawa
Journal:  Hepatol Res       Date:  2010-06       Impact factor: 4.288

5.  Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy.

Authors:  E Formann; P Steindl-Munda; H Hofer; W Jessner; U Bergholz; C Gurguta; P Ferenci
Journal:  Aliment Pharmacol Ther       Date:  2006-02-15       Impact factor: 8.171

6.  A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.

Authors:  Mark G Swain; Ming-Yang Lai; Mitchell L Shiffman; W Graham E Cooksley; Stefan Zeuzem; Douglas T Dieterich; Armand Abergel; Mário G Pessôa; Amy Lin; Andreas Tietz; Edward V Connell; Moisés Diago
Journal:  Gastroenterology       Date:  2010-07-14       Impact factor: 22.682

7.  Efficacy of peginterferon alpha-2A and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C.

Authors:  Vadim Brjalin; Riina Salupere; Tatjana Tallo; Tatiana Kuznetsova; Ljudmilla Priimägi; Valentina Tefanova
Journal:  Cent Eur J Public Health       Date:  2012-06       Impact factor: 1.163

8.  A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.

Authors:  Tsugiko Oze; Naoki Hiramatsu; Eiji Mita; Norio Akuta; Naoya Sakamoto; Hiroaki Nagano; Yoshito Itoh; Shuichi Kaneko; Namiki Izumi; Hideyuki Nomura; Norio Hayashi; Tetsuo Takehara
Journal:  Hepatol Res       Date:  2013-01       Impact factor: 4.288

9.  Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.

Authors:  Sarah Maylin; Michelle Martinot-Peignoux; Rami Moucari; Nathalie Boyer; Marie-Pierre Ripault; Dominique Cazals-Hatem; Nathalie Giuily; Corinne Castelnau; Ana Carolina Cardoso; Tarik Asselah; Cyrille Féray; Marie Hélène Nicolas-Chanoine; Pierre Bedossa; Patrick Marcellin
Journal:  Gastroenterology       Date:  2008-05-21       Impact factor: 22.682

10.  Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir.

Authors:  William M Lee; Julie E Polson; D Spencer Carney; Bogachan Sahin; Michael Gale
Journal:  J Infect Dis       Date:  2005-08-10       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.